ENGN
Engene Holdings Inc
NASDAQ · Biotechnology
$9.55
+0.69 (+7.79%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 102.93M | 108.44M | 88.87M |
| Net Income | -18,276,199 | -22,730,064 | -15,420,094 |
| EPS | — | — | — |
| Profit Margin | -17.8% | -21.0% | -17.4% |
| Rev Growth | +6.4% | +6.6% | +8.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 170.75M | 147.61M | 160.40M |
| Total Equity | 412.47M | 470.09M | 467.00M |
| D/E Ratio | 0.41 | 0.31 | 0.34 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -27,166,221 | -28,388,210 | -21,820,067 |
| Free Cash Flow | -19,844,248 | -21,752,544 | -13,746,863 |